. Author manuscript; available in PMC: 2024 Aug 14.

Published in final edited form as: Pharmacotherapy. 2017 Nov 27;37(12):1489–1497. doi: 10.1002/phar.2049

Table 2.

Clinical Inputs for All Patient Subpopulations in Model

Input	Elderly^5,11, %	Cancer¹², %	Concomitant antibiotics¹³, %	Renal impairment¹⁴, %
Initial treatment failure rate^a,b
Fidaxomicin	15.18	14.94	10.00	22.20
Vancomycin	15.69	26.04	20.59	20.90
Rate of first CDAD recurrence
Fidaxomicin	16.07	13.51	16.85	19.51
Vancomycin	29.29	29.58	29.17	32.56
Rate of second CDAD recurrence^c,17
Fidaxomicin	20.30	20.30	20.30	20.30
Vancomycin	32.30	32.30	32.30	32.30

CDAD = Clostridium difficile–associated diarrhea.

Efficacy rates for vancomycin 125 mg and vancomycin 250 mg are assumed to be the same.

Initial treatment failure rates for subpopulations from published subset phase III data; fidaxomicin was shown to be statistically noninferior to vancomycin for initial cure in the overall population and superior in sustained clinical response (clinical response without recurrence or death) at 25 days.

Rate of second CDAD recurrence assumed to be the same for all subpopulations.